Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
Pheburane | Sodium phenylbutyrate | Urea cycle disorders | List | Complete | ||
Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lokelma | sodium zirconium cyclosilicate | Hyperkalemia, adults | Do not reimburse | Complete | ||
Sovaldi | Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Sovaldi | sofosbuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Epclusa | sofosbuvir / velpatasvir | Hepatitis C, chronic | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Vosevi | sofosbuvir velpatasvir voxilaprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Epclusa | Sofosbuvir/ velpatasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Vesicare | Solifenacin succinate | Bladder, overactive | List with clinical criteria and/or conditions | Complete |